VCP
ALNY icon

Verus Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Verus Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$11K Hold
100
– – ﹤0.01% 964
2019
Q4 		$12K Buy
+100
New +$9.97K ﹤0.01% 1051

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Verus Capital Partners's ALNY Position: Q1 2020 in Review

Verus Capital Partners held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2020 at 100 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Verus Capital Partners first reported a position in ALNY in Q4 2019 and has held it in 2 quarters since. The position peaked at $12K in Q4 2019. 330 funds tracked by Wall St. Rank hold ALNY as of Q1 2020.

  • Verus Capital Partners held 100 shares of Alnylam Pharmaceuticals worth $11K as of Q1 2020.
  • Verus Capital Partners left its Alnylam Pharmaceuticals share count unchanged in Q1 2020.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #964 holding.
  • Verus Capital Partners first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Alnylam Pharmaceuticals position peaked at $12K in Q4 2019.
  • 330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.